Eli Lilly crossed the $1 trillion mark, and instantly every politician in Indiana acted like we should throw a parade down Meridian Street. Maybe roll out a golden syringe as the grand marshal. Maybe build a statue of a CEO holding a GLP-1 vial like it’s the Holy Grail.
Let’s get something straight:
This is not a medical miracle.
This is a financial crime scene with balloons.
Eli Lilly didn’t reach $1 trillion because they saved lives — they reached it because they sell the same miracle drug every month for the rest of your natural existence. They’ve turned chronic illness into a subscription service. Netflix, but for diabetes. Spotify, but with needles and side effects.
Their GLP-1 drugs brought in over $10 billion last quarter, and they still have the audacity to act like they’re philanthropists instead of the most successful drug traffickers in the Midwest.
And while Hoosiers ration insulin and cut pills in half, Lilly executives are flying over Indiana in private jets shaped like dollar signs.
But don’t worry — Indiana’s politicians are right there licking the crumbs off Lilly’s table, especially at the LEAP district in Lebanon, a project that’s basically a $3 billion “Welcome Home” basket for a corporation that made its money exploiting the very diseases they claim to fight.
Lebanon’s city leadership, state officials, and the IEDC practically tackled each other trying to prove who loves Eli Lilly more. All while the public gets gaslit into believing this whole thing is about “jobs” and “innovation.”
Jobs?
For who?
Robots?
Accountants?
Executives who need a new indoor pickleball court?
Let’s not pretend the LEAP project is about improving anything but Eli Lilly’s already monstrous profit pipeline. It is — and always has been — a state-funded handout to a company too rich to need help.
The state bends over backwards.
Lilly bends Indiana over forwards.
It’s a perfect circle of exploitation.
Let’s talk about morality.
Yes, I said morality.
Because Lilly doesn’t have any.
They’ve had decades to cure diabetes.
Decades.
More scientists than the cast of The Big Bang Theory.
More funding than the CDC.
But they didn’t cure it.
Why?
Because curing diabetes would kill the profit stream.
You can’t sell a cure every month forever.
You can, however, sell Mounjaro for $1,000 a month until the sun burns out.
That’s why their R&D is laser-focused on treatments, management, control, maintenance every word that means “we’ll keep you alive just enough to keep billing you.”
This company is not a healthcare provider.
This company is a trillion-dollar maintenance plan for human suffering.
And Indiana rolls out the red carpets like we’re grateful for the privilege of being exploited.
Let’s stop pretending:
- Eli Lilly is not a savior.
- Eli Lilly is not a hero.
- Eli Lilly is not improving Indiana.
- Eli Lilly is not bringing hope.
Eli Lilly is the most profitable drug dealer in America and Indiana just built them a luxury compound.
And when the ribbon is cut and the cameras roll, remember this:
The same company politicians worship is the same company that made its fortune off diseases they will never cure — because curing them would require sacrificing a single dollar of profit.
If Indiana had this much enthusiasm for farmers, teachers, nurses, or small business owners, our entire state would be thriving.
But no — we give all our love to a company that charges people four digits a month to stay alive.
The way Lebanon officials behave, you’d think they were auditioning for “Corporate Servant Idol.”
They don’t ask questions.
They don’t push back.
They don’t defend residents.
They nod, smile, sign, approve, and sprint to microphones like they just solved world hunger.
Meanwhile, the people they represent?
They get gaslit.
- Concerned about water? “Stop fearmongering.”
- Concerned about land use? “Anti-progress.”
- Concerned about long-term costs? “NIMBY.”
- Concerned about giving billions in benefits to a trillion-dollar drug dealer? “Shhh, Lilly is talking.”
Lebanon leaders should be fighting for their residents.
Instead, they’re fighting to impress Eli Lilly.